1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. DexCom, Inc.
  6. News
  7. Summary
    DXCM   US2521311074

DEXCOM, INC.

(DXCM)
  Report
Delayed Nasdaq  -  05/26 04:00:00 pm EDT
280.63 USD   -0.25%
12:36aDEXCOM : Statement of Changes in Beneficial Ownership (Form 4)
PU
05/25TRANSCRIPT : DexCom, Inc. Presents at Piper Sandler Ophthalmology and Diabetes Symposium, May-25-2022 01:00 PM
CI
05/24SECTOR UPDATE : Health Care Stocks Returning to Positive Ground in Late Trade
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Dexcom, Inc. Reports Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Fiscal Year Ended December 31, 2021; Revenue Guidance for the Fiscal Year 2022

01/10/2022 | 08:01am EDT

Dexcom, Inc. reported preliminary unaudited revenue guidance for the fourth quarter ended December 31, 2021, for the fiscal year 2021 and revenue guidance for the fiscal year 2022. For the quarter, the company expects the revenue to be approximately $698 million, an increase of 23% over the fourth quarter of 2020. For the fiscal year 2021, the company expects the total preliminary, unaudited revenue to be approximately $2.448 billion, an increase of more than 27% over 2020. For the fiscal year 2022, the company expects the revenue to be in the range of $2.82 billion to $2.94 billion. Representing expected growth of approximately 15% to 20% over 2021.


© S&P Capital IQ 2022
All news about DEXCOM, INC.
12:36aDEXCOM : Statement of Changes in Beneficial Ownership (Form 4)
PU
05/25TRANSCRIPT : DexCom, Inc. Presents at Piper Sandler Ophthalmology and Diabetes Symposium, ..
CI
05/24SECTOR UPDATE : Health Care Stocks Returning to Positive Ground in Late Trade
MT
05/24SECTOR UPDATE : Health Care Stocks Sliding Tuesday
MT
05/24GLOBAL MARKETS LIVE : Broadcom, Airbnb, Roche, Toyota, Uber
05/24SECTOR UPDATE : Health Care Stocks Mixed Premarket Tuesday
MT
05/24SECTOR UPDATE : Health Care
MT
05/24DexCom In Talks To Buy Insulet, Sources Say
MT
05/23Dexcom Reportedly in Talks to Acquire Insulet
CI
05/23Dexcom Announces Upcoming Conference Presentation
BU
More news
Analyst Recommendations on DEXCOM, INC.
More recommendations
Financials (USD)
Sales 2022 2 917 M - -
Net income 2022 380 M - -
Net cash 2022 63,8 M - -
P/E ratio 2022 75,4x
Yield 2022 -
Capitalization 27 537 M 27 537 M -
EV / Sales 2022 9,42x
EV / Sales 2023 7,84x
Nbr of Employees 6 300
Free-Float 99,5%
Chart DEXCOM, INC.
Duration : Period :
DexCom, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DEXCOM, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 280,63 $
Average target price 527,12 $
Spread / Average Target 87,8%
EPS Revisions
Managers and Directors
Kevin Ronald Sayer Chairman, President & Chief Executive Officer
Jereme M Sylvain Chief Financial Officer & EVP-Finance
Andrew K. Balo EVP-Global Medical Affairs, Access & Evidence
Jacob S. Leach Chief Technology Officer & Executive VP
Donald M. Abbey Executive VP-IT, Quality & Regulatory Affairs
Sector and Competitors
1st jan.Capi. (M$)
DEXCOM, INC.-47.61%27 605
ABBOTT LABORATORIES-19.58%198 189
MEDTRONIC PLC2.02%141 586
BECTON, DICKINSON AND COMPANY2.60%71 882
HOYA CORPORATION-19.84%39 348
BAXTER INTERNATIONAL INC.-12.41%37 860